Cancer genome sequencing studies have identified numerous driver genes, but the relative timing of mutations in carcinogenesis remains unclear. The gradual progression from premalignant Barrett's esophagus to esophageal adenocarcinoma (EAC) provides an ideal model to study the ordering of somatic mutations. We identified recurrently mutated genes and assessed clonal structure using whole-genome sequencing and amplicon resequencing of 112 EACs. We next screened a cohort of 109 biopsies from 2 key transition points in the development of malignancy: benign metaplastic never-dysplastic Barrett's esophagus (NDBE; n = 66) and high-grade dysplasia (HGD; n = 43). Unexpectedly, the majority of recurrently mutated genes in EAC were also mutated in NDBE. Only TP53 and SMAD4 mutations occurred in a stage-specific manner, confined to HGD and EAC, respectively. Finally, we applied this knowledge to identify high-risk Barrett's esophagus in a new non-endoscopic test. In conclusion, mutations in EAC driver genes generally occur exceptionally early in disease development with profound implications for diagnostic and therapeutic strategies.
Most epithelial cancers develop gradually from preinvasive lesions, in some instances after an initial metaplastic conversion. Research to characterize the genomic landscape of cancer has focused on established invasive disease with the goal of developing biomarkers for personalized therapy 1 . However, it is becoming increasingly clear that extensive genomic heterogeneity is present in the majority of advanced cancers 2 . The most appropriate therapeutic targets are therefore those mutations that occur early in the development of disease and are thus clonal in the resulting malignancy. The identification of causative mutations occurring early in pathogenesis is also pivotal to developing clinically useful biomarkers. In this context, mutations occurring at disease stage boundaries, for example, the transition from nondysplastic epithelium to dysplasia and then to cancer, would be most informative. The evidence thus far on the genetic evolution of cancer from premalignant lesions suggests that the accumulation of mutations is stepwise [3] [4] [5] . In the most well-studied example, the adenomadysplasia-colorectal adenocarcinoma progression sequence, it has been possible to assign timings for mutations in a limited number of candidate genes by comparative lesion sequencing 3 . More recent studies have sought to use statistical algorithms to infer the life history 4,5 of a tumor from single samples.
EAC arises from metaplastic Barrett's esophagus in the context of chronic inflammation secondary to exposure to acid and bile 6, 7 . Barrett's esophagus lends itself well to studies of genetic evolution owing to the repeated sampling of mucosa during clinical surveillance before therapeutic intervention 8 . Previous studies of EAC and Barrett's esophagus have generally used candidate gene approaches with the goal of identifying clinical biomarkers to complement histological examination, which is an approach fraught with difficulties 8, 9 . Data from high-density SNP arrays and exome sequencing studies are now accumulating, with a plethora of mutations identified in many different genes 10, 11 . However, little work has yet focused on the precise ordering of these alterations in large cohorts of individuals with premalignant disease and associated clinical follow-up data.
Recently, Agrawal et al. performed exome sequencing on 11 EAC samples and 2 samples of Barrett's esophagus adjacent to the cancer. Intriguingly, the majority of mutations were found to be present even in apparently normal Barrett's esophagus 12 , similar to the observation in colorectal adenocarcinoma. This finding raises the possibility that, before progression to malignancy, mutations that predict risk of progression might be detectable in cytologically benign tissue.
Ordering of mutations in preinvasive disease stages of esophageal carcinogenesis
A r t i c l e s
However, it is unclear to what extent the same mutations might be present in Barrett's esophagus tissue from individuals who have not progressed to cancer. This question is noteworthy as the majority of individuals with Barrett's esophagus will not progress to cancer, and somatic alterations occurring early, before dysplasia, are unlikely to provide clinically discriminatory biomarkers. Biomarker research in this area is critical because current endoscopic surveillance strategies are increasingly recognized to be ineffective 13 , and novel approaches are therefore required 14, 15 .
The aims of this study were (i) to identify a list of candidate recurrently mutated genes in EAC; (ii) to accurately resolve the stage of disease at which mutation occurs, thereby providing insight on the role of these recurrent mutations in cancer progression; and (iii) to test the usefulness of these mutations in clinical applications, that is, using the non-invasive, non-endoscopic cell sampling device the Cytosponge.
RESULTS

High mutation burden and unusual mutational signature in EAC
The discovery cohort (22 EACs subjected to whole-genome sequencing; Fig. 1 Table 2 ; normal squamous tissue or blood was used as outlined in Supplementary Table 1) .
We identified a median of 16,994 somatic single-nucleotide variants (SNVs; range of 4,518-56,528) and 994 small indels (range of 262-3,573) per sample. In this final data set, a total of 1,086 coding-region mutations were subjected to verification as part of a larger pipeline benchmarking study (Online Methods). We used ultra-deep targeted resequencing, achieving a median coverage of >13,000-fold, and confirmed 1,081 mutations (99.5%) as somatic. Using Sanger sequencing, 23 of 25 indels (92%) were verified as real and somatic. As observed by Dulak et al. in the intervening time since our study commenced 11 , the most frequent mutation type across the discovery cohort was T:A>G:C transversions, with a striking enrichment at CTT trinucleotides (Supplementary Fig. 1 ). This enrichment for T:A>G:C transversions differentiates EAC from other cancers that have been studied by whole-genome sequencing, including breast, colorectal and hepatocellular cancers [16] [17] [18] .
Targeted amplicon resequencing in a validation cohort of EACs
To highlight the genes most likely to be relevant in the development of EAC in individuals with Barrett's esophagus, we sought to determine the degree to which the mutated genes identified in our discovery cohort (n = 22 cases) were representative of the spectrum of mutations in an expanded cohort. Hence, a final list of 26 genes that were either mutated above the background rate or in pathways of interest was selected (Supplementary Note) and tested in a larger cohort (90 additional EACs; Table 1 and Supplementary  Table 3 ) using targeted amplicon resequencing. The findings confirmed and extended those of our discovery cohort and previous work from others 11, 12, 19 , including the identification of recurrent mutations in SWI/SNF complex genes, such as ARID1A (Supplementary Fig. 2) . Analysis of loss of ARID1A protein expression by immunohistochemistry in a cohort of 298 additional EACs found absent or decreased expression in 41% of samples (122/298). This finding suggests that alternative mechanisms of ARID1A downregulation might be present, although we did not identify any large-scale structural variants in the whole-genome sequencing data from our discovery cohort (data not shown).
We next combined the data from both the discovery and validation cohorts and identified 15 genes that were mutated in 4 or more samples (Fig. 2) . These included genes previously identified as EAC candidate genes and several new candidates: MYO18B, SEMA5A and ABCB1. Comparison with recent EAC exome sequencing from Dulak et al. confirmed that these genes were recurrently mutated in an external data set (Supplementary Table 4) . TP53 was mutated in the majority of cases; however, 31% of cases had wild-type TP53. Although we did not have enough power to detect mutually exclusive mutations in our cohort, we could detect significantly co-occurring mutations. SEMA5A and ABCB1 mutations occurred more often in the same tumor than would be expected by chance (BenjaminiHochberg adjusted P value = 0.0021), although the reason for this association remains unclear.
Similar mutation frequency across disease stages
The stage specificity of mutations can be determined by examining cases at discrete stages of Barrett's esophagus carcinogenesis. Mutations occurring at disease stage boundaries would be candidate biomarkers of malignant progression. In addition, mutations occurring early in the development of disease should represent ideal targets for new therapeutic interventions because of their presence in the majority of cells in more advanced lesions owing to clonal expansion early in the natural history of tumors. We therefore sought to identify the mutation status of the 26 genes in our panel in Barrett's esophagus samples obtained from a prospective cohort of individuals undergoing endoscopic surveillance. This cohort included 109 Barrett's esophagus biopsies from 79 individuals (Fig. 1) . We selected 66 NDBE samples from 40 individuals with Barrett's esophagus for whom there was no evidence for progression to dysplasia or malignancy (median follow-up time of 58 months, range of 4-132 months) and 43 Barrett's esophagus biopsy samples from 39 individuals of histopathologically confirmed HGD, the stage just before the development of invasive EAC ( 
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A r t i c l e s
The findings were striking and unexpected. In the NDBE cohort, 21 of 40 individuals (53%) were found to have mutations in their Barrett's esophagus segment ( Fig. 3a) , with several biopsies containing multiple mutations (Supplementary Table 5 ). In total, we identified 29 SNVs and 7 indels in this cohort. Notably, the mutations identified in NDBE occurred in several genes previously identified as drivers in EAC 11, 19 and other cancers 21, 22 , including in SMARCA4, ARID1A and CNTNAP5 (Fig. 3b) . Of interest, 7 of the 29 SNVs were mutations at T:A base pairs. Of these, 5 of 7 (71%) occurred at TT dinucleotide sequences, the mutational context identified as highly enriched in the EAC whole-genome sequencing data. Thus, this mutational process might well be active at the earliest stages of disease. Of the 43 HGD biopsy samples, 39 (91%) were found to have mutations in at least 1 of the genes in our panel, with a total of 67 SNVs and 7 indels. Hence, rather than the frequency of mutation in a given gene increasing across disease stages, we observed that, for the vast majority of genes, the mutational frequency was not significantly different between NDBE, HGD and EAC (Fisher's exact test with BenjaminiHochberg correction for multiple testing; Fig. 3b and Supplementary Table 6 ). For 2 genes, MYO18B and ARID1A, we performed amplicon sequencing in an additional 25 NDBE and 11 HGD samples, increasing the cohort to a total of 91 NDBE and 54 HGD samples, but we did not identify any significant difference in the frequency of mutation between disease stages (Supplementary Table 7 ). Only TP53 (P < 0.0001) and SMAD4 (P = 0.0061) (Fig. 3b,c) exhibited mutational frequencies that would distinguish between disease stages and thus identify progression toward malignancy. TP53 was found to be recurrently mutated in both HGD (72%) and EAC (69%) samples but was mutated in only a single NDBE sample (2.5%). SMAD4 was mutated at a lower frequency (13%) and, intriguingly, was only found in EAC, the invasive stage of disease.
Clonal analysis of recurrent mutations
Having identified the occurrence of mutations in the earliest stages of disease development, we next sought to determine whether these mutations were fully clonal or subclonal in our original discovery cohort of 22 EACs. For each of the 15 genes mutated in ≥4 samples from our expanded cohort, we combined our high-depth resequencing of SNVs, copy number variant data and loss-of-heterozygosity (LOH) analysis to determine the fraction of tumor cells containing the mutation (Supplementary Note). If a mutation occurs at the earliest stage of disease development, before clonal expansion of the malignancy, we would expect that the mutation would be present in all cells of the tumor. For 7 of 15 genes-SMAD4, TP53, ARID1A, SMARCA4, TLR4, CDKN2A and PNLIPRP3-this was the case. Mutation in the other eight genes (MYO18B, TRIM58, CNTNAP5, ABCB1, PCDH9, UNC13C, SEMA5A and CCDC102B) was not always present in the major clone ( Supplementary Fig. 3 ), suggesting that mutation of these genes might be selected for at multiple stages of tumorigenesis.
Application of mutational knowledge to a diagnostic test
The current clinical strategy for patients with Barrett's esophagus involves regular endoscopic examinations to try to identify patients TP53  SMAD4  ARID1A  MYO18B  SEMA5A  CDKN2A  TRIM58  CNTNAP5  ABCB1  PCDH9  SMARCA4  PNLIPRP3  UNC13C  TLR4  CCDC102B   TP53  SMAD4  ARID1A  MYO18B  SEMA5A  CDKN2A  TRIM58  CNTNAP5  ABCB1  PCDH9  SMARCA4  PNLIPRP3  UNC13C  TLR4 The number in bold denotes the total number of mutations for each gene. Genes with 4 or more mutations in our EAC discovery and validation cohorts (combined total of 112 cases) were included. The proportions of missense, nonsense or splice-site, and indel mutations are shown. The matrix below shows the number of samples with mutations in both genes for each possible pairing of genes. The red highlighted box indicates significantly co-occurring mutations (significance was assessed empirically from 100,000 permutations, and the false discovery rate was nominally controlled using the Benjamini-Hochberg procedure to be less than 0.05; the co-occurrence of mutations in ABCB1 and SEMA5A has an adjusted P value of 0.0021).
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A r t i c l e s with dysplasia who are at high risk of progression to adenocarcinoma. This approach is highly controversial because of inherent difficulties in the accurate identification of dysplastic lesions, and recent data suggest that endoscopic surveillance of Barrett's esophagus is not effective 13, 23 . The difficulties involved in endoscopic surveillance for Barrett's esophagus include sampling bias inherent in random-biopsies protocols and the subjective and time-consuming histopathological diagnosis of dysplasia. We therefore developed a new approach that has the potential to overcome these limitations of Barrett's esophagus surveillance. The strategy comprises a non-endoscopic device called the Cytosponge, which can be provided to patients in the primary care setting. This device collects cells from the entire esophageal mucosa, thus avoiding sampling bias, and can be combined with objective analysis of biomarkers for diagnosis 24, 25 . Thus far, our focus has been on a biomarker for diagnosing Barrett's esophagus; however, because most patients with Barrett's esophagus will not progress to EAC, this biomarker for Barrett's esophagus needs to be combined with a biomarker (or a panel of biomarkers) to identify high-risk dysplastic patients. From the aforementioned sequencing data, TP53 mutations fit the criteria of a good candidate marker for risk stratification, as these mutations discriminate between individuals with and without HGD, the key point of therapeutic intervention. Although the device samples abnormal tissue, the majority of cells collected are from normal gastric glandular tissue at the top of the stomach, as well as normal squamous areas of the esophagus, and any mutant DNA would therefore theoretically be in the minority, requiring a very sensitive assay (Supplementary Fig. 4 ). This situation is analogous to the detection of tumor cell-free DNA in blood as a biomarker in advanced malignant disease: sensitive assays have been developed to detect extremely low levels of mutant DNA against normal background 26, 27 . We therefore took an analogous approach to detect mutations in Cytosponge material.
To determine whether mutations in Barrett's esophagus lesions could be detected in material collected from the Cytosponge, we first tested mutations previously identified in endoscopic Barrett's esophagus biopsies. Four individuals with HGD had TP53 mutations and had also swallowed the Cytosponge (twice in the case of subject 4). For all four individuals, the specific TP53 mutations were detected at an allele fraction (proportion of variant reads) of between 0.04 and 0.24 ( Table 2) .
We then tested whether we could detect unknown TP53 mutations in material collected using the Cytosponge, as this ability would be required for a clinical test. We amplified the majority of the coding region of TP53 (1,019/1,182 bp; 86%) by multiplexed PCR and sequenced the amplified DNA by massively parallel sequencing. TP53 mutations were called de novo using TAm-seq (tagged-amplicon deep sequencing) 26 on samples from controls (no Barrett's esophagus) and individuals with Barrett's esophagus with no dysplasia, as well as individuals with Barrett's esophagus with HGD. As we expected, no TP53 mutations were identified in samples from controls or individuals with Barrett's esophagus with no dysplasia (Fig. 4a) (Fig. 4b) .
DISCUSSION
Barrett's esophagus is the only known precursor lesion of EAC, co-occurring in >80% of cases presenting de novo 28 ; however, the majority of individuals with Barrett's esophagus will never progress to invasive disease 29 . There is therefore a need for sensitive and specific biomarkers that can identify those who are at risk of progression. As long ago as the Nowell hypothesis, a stepwise selection of genomic mutations has been assumed to be necessary for cancer development 30 . Somatic genomic variants should therefore be highly sensitive and specific markers of disease stage. By screening for our panel of recurrently mutated genes in a cohort of individuals with Barrett's esophagus who had never developed dysplasia and a cohort of individuals with Barrett's esophagus with HGD, we hoped to identify a stepwise accumulation of mutations across these disease stages. Surprisingly, we identified numerous mutations occurring in never-dysplastic Barrett's esophagus at detectable allele fractions (>10%). Intriguingly, the most prevalent gene mutations in EAC were also present at similar frequencies in NDBE and HGD samples including mutations in cancer-associated genes, for example ARID1A and SMARCA4, which encode members of the SWI/SNF chromatin-remodeling complex. These data demonstrate the complex mutational landscape that may be present even within tissue with a very low risk of malignant progression that has an entirely benign histopathological appearance. The exact role of these mutations at such an early stage of disease development remains unclear. However, it is known that clonal expansions occur frequently in Barrett's esophagus, and it is possible that these mutations provide an increase in fitness for a clone without leading to disruption of the epithelial architecture or providing the necessary cellular characteristics for invasion. A similar observation has been reported in endometrial cancer. In the normal population, ~35% of women harbor PTEN-mutant glands in their endometrial tissue, yet the lifetime risk of endometrial cancer is ~2.5% (ref. 31) . Our result has substantial implications for the specificity of tests aiming to use highly sensitive detection of mutations for the early diagnosis of malignancy 32 . Biomarkers predicting individuals at risk for cancer need to have substantial predictive power to distinguish between those who will and will not develop cancer. In our study, almost all recurrently mutated genes in EAC, including ABCB1, CNTNAP5 and MYO18B, among others, are ruled out for use as surveillance tools for progression risk. Only mutation in TP53 and SMAD4 accurately defined the boundaries of disease states. The fact that mutation of SMAD4 was only found in EAC provides a clear genetic distinction between EAC and HGD. However, the low frequency of SMAD4 mutation (13%) makes it a suboptimal candidate for biomarker development. Furthermore, HGD rather than EAC is now the ideal point of clinical intervention owing to the advent of endoscopic therapy. We therefore focused on TP53 for the proofof-principle Cytosponge study. Sequencing technologies are now being introduced to routine clinical use, and genes of interest can be sequenced rapidly and with exquisite sensitivity, providing a quantitative readout 26 .
We detected mutations in 86% of HGD Cytosponge samples using a simple, clinically applicable test. To improve the sensitivity of any early detection program, it will also be important to identify the genetic or epigenetic changes that drive HGD and EAC in the minority of patients without a detectable TP53 mutation. In addition, as genetic diversity has been shown to predict progression to Barrett's esophagus, it may be possible to perform somatic mutation testing looking at both the presence and relative proportions of mutations in a panel of genes to identify patients with high-risk disease 33 .
In conclusion, NDBE harbors frequent mutations affecting recurrently mutated genes in EAC. Given the low rate of progression to malignant disease in NDBE, the role of these mutations on the road to malignancy is unclear. It is generally accepted that the mutations observed in a tumor are accrued in a linear progression, with each step bringing the clone closer to the invasive endpoint. Our observation of mutations in almost all of the recurrently mutated genes in the tissue of individuals who have not gone on to develop malignancy argues against a major role of these mutations in the progression toward cancer. Although their recurrent nature suggests a role in clonal expansion at the premalignant stage, these mutations do not seem to provide any long-term increase in the likelihood of malignant progression. It is likely that sequencing of additional cohorts with greater sample numbers and differing demographics will identify further recurrently mutated genes in EAC, and these too will need careful analysis to determine the disease stage at which they occur.
From a clinical perspective, because the vast majority of recurrently mutated genes in EAC do not differentiate between the premalignant and malignant stages of disease, they therefore cannot be applied in a simple binary test-characterizing samples as mutant or non-mutant-as biomarkers of malignant progression. The Cytosponge provides a representative sample of the entire esophageal mucosa and, coupled with high-throughput sequencing, R157fs  C176F  H193Y  I195T  R196*  Y220S  Y234F  C242Y  G244S  R248W  R273C  R273H  R282W  E285K  E298K  R342 
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A r t i c l e s is capable of sensitive and objective detection of HGD. This approach could be readily adapted as understanding of the genetic basis for this disease evolves. Furthermore, our systematic molecular approach to identify key mutations involved in the steps distinguishing preinvasive from invasive disease has applicability to other epithelial cancers amenable to early detection.
ONLINE METHODS
Sample collection, pathology review and extraction. The study was approved by the Institutional Ethics Committees (REC 07/H0305/52 and 10/H0305/1), and all subjects gave individual informed consent. For the discovery cohort, patients with EAC were recruited prospectively, and samples were obtained either from surgical resection or by endoscopic ultrasound (EUS). This was an exploratory pilot with no prespecified effect size. Blood or normal squamous esophageal samples, distant by at least 5 cm from the tumor, were used as germline reference. All tissue samples were snap frozen in liquid nitrogen immediately after collection and stored at −80 °C. Before DNA extraction, one section was cut from each esophageal tissue sample, and staining with hematoxylin and eosin was performed. Cancer samples were deemed suitable for DNA extraction only after consensus review by two expert pathologists had confirmed tumor cellularity of ≥70%. Where blood was not available, the same review process was applied to normal esophageal samples to ensure that only squamous epithelium was present. For the discovery cohort, 127 cases were screened from 2 centers (Cambridge and Southampton). Sixty-three cases had the 70% cellularity required to meet ICGC criteria, and, of these, 22 tumor-normal pairs had sufficient quality and quantity of DNA extracted (total yield of ≥5 µg) and were submitted for whole-genome sequencing. Of the remaining 105 cases available, 90 had >50% cellularity, and all of these had sufficient DNA for amplicon sequencing. For all cases in the discovery and validation cohorts, there was a 260/280 ratio of 1.8-2.1. For the preinvasive disease cohort, we screened our entire 10-year prospective Barrett's cohort of >500 patients and selected cases for which there was frozen material available and for which review of the frozen section revealed a homogeneous grade of dysplasia in expert histopathological review. Cytosponge samples were all those available as part of an interim analysis from an ongoing prospective case-control study (BEST2). DNA was extracted from frozen esophageal tissue using the DNeasy kit (Qiagen) and from blood samples using the Nucleon Genomic Extraction kit (Gen-Probe) according to the manufacturers' instructions. For validation, DNA was extracted using the AllPrepDNA/RNA Mini kit (Qiagen) according to the manufacturer's instructions.
Whole-genome sequencing. A single library was created for each sample, and 100-bp paired-end sequencing was performed under contract by Illumina to a typical depth of at least 50×, with 94% of the known genome being sequenced to at least 8× coverage and achieving a Phred quality of at least 30 for at least 80% of mapping bases. Typically, five lanes of a HiSeq 2000 (Illumina) flow cell were sufficient to achieve this, but samples were not multiplexed, so some exceeded these minimum standards by a large margin. Filtered read sequences were mapped to the human reference genome (GRCh37) using BurrowsWheeler Alignment (BWA) 34 , and duplicates were marked using Picard. As part of an extensive quality assurance process, quality control metrics and alignment statistics were computed on a per-lane basis. Aggregated quality control for each discovery cohort sample is given in Supplementary Table 9 . Details of any tiles within flow cells that were removed after quality control are shown in Supplementary Table 10 .
The FastQC package was used to assess the quality score distribution of the sequencing reads and enabled the identification of three lanes of sequencing that required trimming owing to a drop in quality in the later cycles of sequencing (see details in Supplementary Table 11 ).
Whole-genome sequencing mutation calling. Somatic SNVs were predicted using SomaticSniper V1.0.2 (ref. 35 ) run with the following command: somaticsniper -q 1 -Q 15 -F vcf -J -r 0.001000 -T 0.850000 -N 2 -s 0.01 -f. Output from SomaticSniper was then filtered using the following criteria derived from comparison of heuristic filters applied to SomaticSniper and VarScan 2 (ref. 36) and implemented using scripts provided in Koboldt et al. 36 and custom scripts (homopolymer filter). The filtering criteria were (i) germline and tumor sample coverage of ≥10, (ii) average variant position in the read between positions 10 and 90, (iii) percentage of supporting reads from each strand of ≥1% and ≤99%, (iv) total number of supporting reads of ≥4, (v) average distance of variant base from effective 3′ end of supporting reads of ≥20 bp, (vi) average mapping quality difference between reference and variant-supporting reads of <30, (vii) average difference in length of trimmed sequences between reference and variant reads of <25 bp, (viii) mismatch quality sum difference of <100 between reference and variant reads, (ix) adjacent homopolymer <5 bp away, and (x) nearest indel ≥40 bp away. In addition, all variants were compared to dbSNP129 and removed if overlapping with predicted germline SNPs. A median of 99.7% of the mappable genome was covered by at least tenfold in the tumor and matched germline sample and was thus defined as callable (Supplementary Table 12) .
Candidate somatic indels were taken as the consensus between SAMtools 37 and Pindel 38 , filtered to exclude indels present in the matched normal genome of any of the 22 samples (including non-consensus indel calls). Indels falling within coding regions and splice sites were manually inspected to generate a final list of calls. Variants were annotated with sequence ontology terms to describe consequence and position relative to Ensembl gene annotations. SNVs and indels were also annotated with matching or nearest features in UniSNP.
Verification of indel variants by PCR.
A total of 25 coding indels, confirmed by manual review, were randomly selected for verification. Primers (sequences available upon request) were designed to amplify the predicted variant location. PCR was performed on both the tumor and normal DNA, and resulting products underwent Sanger sequencing. All traces were visualized using Chromas lite 2.01 and were manually reviewed for presence of the variant. An indel was considered somatic if it was present only in the tumor trace.
Verification of single-nucleotide variants by targeted resequencing. As part of a larger benchmarking exercise of our SNV calling pipeline, we selected 2,007 SNVs to be verified. These SNVs included those that had failed filters and those that had been predicted using the Illumina pipeline ELAND alignment plus STRELKA. The complete analysis of these data is ongoing, with the overall aim of optimizing the sensitivity of our SNV calling pipeline. After a preliminary analysis and comparison to the ICGC benchmarking exercise, we chose to increase the stringency of our filters for this pilot data set. The verification data in this manuscript are for only those SNVs passing these additional filters. Putative nonsynonymous SNVs (1,330 in total) underwent ultra-high-depth targeted sequencing. For eight samples, all nonsynonymous variants were sent for verification. In the remaining 14 cases, the selected SNVs were restricted to nonsynonymous variants in genes mutated in more than 1 sample. Amplicons were generated, indexed and pooled, and libraries were constructed as described by Shah et al. 39 . Samples were pooled separately, and a single lane of HiSeq 2000 data was generated for each, leading to a typical depth of coverage of 13,855 (interquartile range (IQR) of 3,408 to 39,059 for the amplicons). For 1,086 of these, ≥50-fold coverage was generated for both tumor and normal samples. An SNV was confirmed as somatic if the variant allele frequency was ≤1% in the matched normal sample and ≥2% in the tumor sample, and 1,081 SNVs met these criteria, giving a verification rate of 1,081/1,086 (99.5%).
Mutation validation in independent samples. Mutation validation was performed in a cohort of 90 additional EACs and 109 Barrett's esophagus biopsies, including 43 Barrett's esophagus biopsies with histopathologically confirmed HGD and 66 with no dysplasia. The Access Array microfluidics PCR platform (Fluidigm) together with high-throughput sequencing (Illumina) was used for targeted resequencing.
Amplicons with a median size of 180 bp (range of 100-200 bp) were designed using Fluidigm in-house software (primers available upon request) 26 . After two iterations of primer design, one gene remained uncovered by suitable amplicons (DIRC3), and this gene was removed from further analysis. Hence, in total, 26 genes were selected (Supplementary Tables 13 and 14) . All primers were synthesized with universal sequences (termed CS1 and CS2) appended at the 5′ end.
Target amplification and sample barcoding were performed using the manufacturer's standard multiplex protocol (Fluidigm, Access Array User Guide). Primers were combined into multiplex pools ranging from 1 to 12 primer pairs. The Access Array system was used to combine PCR reagents (FastStart High-Fidelity PCR System, Roche) with 47 DNA samples (50 ng) plus a single npg found in Supplementary Table 17 . Fluidigm barcode primers were used as they contain a sequence that binds to the CS1 and CS2 sequences present in the first TP53 primers as well as the Illumina adaptors. The barcode PCR mix consisted of 1× Q5 master mix, 5% DMSO, a final concentration of 400 nM of each barcode primer pair and 1 µl of undiluted Exostar-treated DNA. Cycling conditions for PCR were as follows: initial denaturation at 98 °C for 30 s followed by 14 cycles of 98 °C for 10 s, 60 °C for 10 s and 72 °C for 30 s. A final extension at 72 °C for 2 min was also included to ensure elongation of all PCR products.
TAm-seq single-nucleotide variant and indel calling for detecting TP53 mutations in Cytosponge samples. Indels were called by selecting outliers from locus-specific distributions of background mutation rates. Candidate insertions and deletions in each sample were compared with insertion and deletion rates at the same locus in samples from every other patient and were scored by means of z scores. Indels with a z score greater than or equal to 10, at least 200× coverage and at least five supporting reads were retained.
